OBJECTIVE: To describe the effects of venlafaxine, fluoxetine and sertraline treatment on mood and behaviour patterns, physical functioning, and tolerability issues in a long-term care environment. DESIGN, SETTING AND PARTICIPANTS: Retrospective cohort analysis of 257 elderly residents of three long-term care facilities in the US who used venlafaxine, fluoxetine or sertraline during a 3-month period. MAIN OUTCOME MEASURES: Indicators of depression, anxiety and sad mood, physical functioning, antidepressant-related adverse events, and the global impression of efficacy. RESULTS: The average age of the participants was 80.6 years. At the 3-month follow-up, more than 85% of the residents recorded no change in indicators of depression, anxiety and sad mood or physical functioning, and there were no statistically significant differences among the three antidepressant drug groups. A marginal improvement in the social interaction indicator was observed among residents who received venlafaxine (11%) compared with those receiving fluox-etine (3%) or sertraline (2%). Antidepressant-related adverse events were infrequent and similar in incidence across the three drug groups. CONCLUSIONS: Indicators of mood and functioning of most residents were stable over the 3-month period and similar among the venlafaxine, fluoxetine and sertraline groups, and no significant differences in the safety profiles of the three drugs were recorded.
OBJECTIVE: To describe the effects of venlafaxine, fluoxetine and sertraline treatment on mood and behaviour patterns, physical functioning, and tolerability issues in a long-term care environment. DESIGN, SETTING AND PARTICIPANTS: Retrospective cohort analysis of 257 elderly residents of three long-term care facilities in the US who used venlafaxine, fluoxetine or sertraline during a 3-month period. MAIN OUTCOME MEASURES: Indicators of depression, anxiety and sad mood, physical functioning, antidepressant-related adverse events, and the global impression of efficacy. RESULTS: The average age of the participants was 80.6 years. At the 3-month follow-up, more than 85% of the residents recorded no change in indicators of depression, anxiety and sad mood or physical functioning, and there were no statistically significant differences among the three antidepressant drug groups. A marginal improvement in the social interaction indicator was observed among residents who received venlafaxine (11%) compared with those receiving fluox-etine (3%) or sertraline (2%). Antidepressant-related adverse events were infrequent and similar in incidence across the three drug groups. CONCLUSIONS: Indicators of mood and functioning of most residents were stable over the 3-month period and similar among the venlafaxine, fluoxetine and sertraline groups, and no significant differences in the safety profiles of the three drugs were recorded.
Authors: B D Lebowitz; J L Pearson; L S Schneider; C F Reynolds; G S Alexopoulos; M L Bruce; Y Conwell; I R Katz; B S Meyers; M F Morrison; J Mossey; G Niederehe; P Parmelee Journal: JAMA Date: 1997-10-08 Impact factor: 56.272
Authors: G Gambassi; F Landi; L Peng; C Brostrup-Jensen; K Calore; J Hiris; L Lipsitz; V Mor; R Bernabei Journal: Med Care Date: 1998-02 Impact factor: 2.983